Stem Cell
Insider

New meta-analyses show umbilical cord blood and MSCs safely improve motor function in kids with cerebral palsy—promising cellular therapies for brain repair.

Gamida Cell received FDA approval for its allogeneic cell therapy, Omisirge: a new expanded cord blood cell source for stem cell transplantation.Omisirge may increase access to stem cell transplants, including among patients from diverse backgrounds.

Bone marrow MSCs, adipose tissue MSCs, umbilical cord MSCs and mononuclear cells have long been used in transplantations for a wide array of treatments. Umbilical cord blood and cord tissue-derived mesenchymal stem cells (UC-MSCs) are undergoing several clinical trial phases to test the safety and efficacy for use in infusions for patients with low back pain (LBP), intervertebral disc degeneration (IVD), and spinal cord injury (SCI).

The most exciting advance in cord blood banking research is the recent discovery of a molecule, UM171, which can dramatically increase the number of stem cells in a cord blood unit. A phase I study is scheduled for December 2014.

Cryo-Cell International is the first private cord blood bank in the U.S. to receive The Foundation for the Accreditation for Cellular Therapy (FACT) accreditation for voluntarily adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization.

At Cryo-Cell, we are continually evaluating ways to improve the quality of our stem cell products to ensure that our specimens are the best in the industry. We have developed a new and improved kit for collection and transportation of cord blood and tissue that provides up to 30 times the protection from extreme temperatures as compared to other kits currently used in the industry. Stem Cells lose viability and functionality when exposed to extreme temperatures.